Enantis’ FGF2-STAB® licensed by Defined Bioscience for use in stem cell media
Enantis recently concluded a licensing agreement with US-based company Defined Bioscience for global use of our patented FGF2-STAB® technology, for use alone and in stem cell media formulations.
“Defined Bioscience is excited to offer FGF2-STAB® to its customers,” said Dr. Steven Rees, CEO of Defined Bioscience. “Thermostable, high-functioning growth factors are critical to the stem cell culture industry, and innovations like this will pave the way for cost-effective, next-generation technologies in the space.”
FGF2-STAB®, originally coined FGF2-G3, was developed by Enantis and Masaryk University, using computational methods to improve thermostability of the wild-type sequence of fibroblast growth factor 2 (FGF2-WT or bFGF). While FGF2-WT quickly destabilizes in standard stem cell culture conditions, FGF2-STAB® retains full biological activity even after five days at 37°C, allowing for a more homogenous, undifferentiated stem cell culture, less frequent medium changes, and weekend-free cell culture scheduling.
“With Defined Bioscience, we share the vision of enabling weekend-free cultivations to scientists all over the world. Therefore, we are happy that our key product will be part of the innovative stem cell culture media being developed at Defined Bioscience” says Roman Badik, CEO of Enantis. “The license agreement we just concluded will be beneficial for both our growing businesses”.